开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
澳大利亚第一季度企业获利季率 -1.3%,前值5.80%。
2026-06-02
澳大利亚第一季度企业获利季率 -1.3%,前值5.80%。
返回
其他消息
2026-06-02
Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-d
Everest Medicines said it has struck an exclusive licence and collaboration with Travere Therapeutics granting Travere exclusive development and commercial rights to EVER001 (civorebrutinib) outside Greater China and certain Southeast Asian countries. Everest will receive a $112.5m upfront payment and is eligible for up to $1.03bn in development, regulatory and commercial milestone payments across up to five indications, plus tiered royalties on future annual net sales ranging from high-single-digit to low-double-digit pct.
2026-06-01
TSMC (TSM.N) shares rose more than 5%, extending gains to a fresh record high.
TSMC (TSM.N) shares rose more than 5%, extending gains to a fresh record high.
Chat with us
, powered by
LiveChat